Clinical efficacy and safety of bevacizumab combined with TP chemotherapy in platinum recurrent ovarian cancer
10.3969/j.issn.1005-1678.2017.06.140
- VernacularTitle:贝伐单抗联合TP方案治疗铂类化疗复发卵巢癌的临床疗效及安全性分析
- Author:
Xi CHEN
;
Yiming ZHU
;
Ping ZHANG
;
Tao ZHU
- Keywords:
ovarian cancer;
chemotherapy;
recurrence;
paclitaxel;
cisplatin;
bevacizumab
- From:
Chinese Journal of Biochemical Pharmaceutics
2017;37(6):366-368
- CountryChina
- Language:Chinese
-
Abstract:
Objective To study the clinical efficacy and safety of bevacizumab combined with TP chemotherapy in platinum recurrent ovarian cancer.Methods34 patients with platinum sensitive recurrent ovarian cancer were seleted as the objects.All patients were treated with bevacizumab plus paclitaxel and cisplatin.The short-term effects, overall survival(OS), progression free survival(PFS) and incidence of adverse reaction during chemotherapy were observed.ResultsThe patients with CR, PR, SD and PD were 3 cases, 24 cases, 5 cases and 2 cases, respectively.The median PFS and median OS of patiens were 12.7months and 26.2 months, respectively.The incidence of decrease in leukocytes, thrombocytopenia, neutrophils, gastrointestinal reactions, elevated levels of transaminase, hypertension, epistaxis, proteinuria, peripheral neuropathy, mucositis were 73.53%, 20.59%, 67.65%, 82.35%, 47.06%, 14.71%, 5.88%, 17.65%, 29.41% and 17.65%, respectively.ConclusionThe bevacizumab combined with TP chemotherapy in treatment of platinum sensitive recurrent ovarian cancer can better relieve the disease, improve the survival time of the patient, the adverse reaction is controllable, and the safety is good, which has the clinical popularization value.
